Prevagen® Races To Raise Awareness For Vitamin Angels At NASCAR Xfinity Series Race In Daytona

DAYTONA, Fla. (Feb. 16, 2018) — Prevagen is teaming up with Vitamin Angels this weekend for the NASCAR Xfinity Series: PowerShares QQQ 300 in Daytona, Florida. The Prevagen sponsored No. 45 car will be driven by Josh Bilicki for JP Motorsports.

Prevagen, the number one selling memory support supplement, recently announced its season long primary sponsorship of Bilicki and has chosen to use this race as an opportunity to raise awareness for the highly rated charity.

Vitamin Angels helps at-risk populations in need – specifically pregnant women, new mothers, and children under five – gain access to lifesaving and life changing vitamins and minerals. Working in over 66 countries where vitamin deficiencies are known to exist, they help children attain good health and the opportunity to lead meaningful and productive lives.

"Quincy Bioscience is proud to utilize our NASCAR racing team sponsorship as a brand megaphone to tell as many people as possible about the excellent life-saving work of Vitamin Angels," said Tom Dvorak, vice president of sales and marketing at Quincy Bioscience, manufacturer of Prevagen. "Prevagen and Vitamin Angels are both committed to helping people live as healthy and as productive lives as possible."

"We're honored to be part of the Prevagen team and excited to share our work with the NASCAR community," said Howard Schiffer, President and Founder of Vitamin Angels.

Prevagen, a brain health support supplement, is clinically shown to help with mild memory issues. Prevagen is safe and uniquely supports brain function. For more information about Prevagen, please visit

About Quincy Bioscience

Quincy Bioscience is a biotechnology company based in Madison, Wisconsin, focused on the discovery, development and commercialization of novel technologies to support brain health, with a specific emphasis on memory support and cognitive health. Quincy Bioscience is set apart by its cutting-edge applications of the patented protein apoaequorin, which has been tested to show improvements in cognition and memory in clinical trials.